WO2003033493A1 - Activateur du recepteur $g(d) active par le proliferateur de peroxisome - Google Patents

Activateur du recepteur $g(d) active par le proliferateur de peroxisome Download PDF

Info

Publication number: WO2003033493A1
Authority: WO; WIPO (PCT)
Prior art keywords: activator; sulfur; alkyl; activated receptor; peroxisome proliferator
Prior art date: 2001-10-12

Application number

PCT/JP2002/010472

Other languages

English (en)

French (fr)

Inventor

Shogo Sakuma

Tomio Yamakawa

Takashi Kanda

Seiichiro Masui

Original Assignee

Nippon Chemiphar Co.,Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-12

Filing date

2002-10-09

Publication date

2003-04-24

2002-10-09 Priority to BRPI0213243A priority Critical patent/BRPI0213243B8/pt

2002-10-09 Priority to IL16135102A priority patent/IL161351A0/xx

2002-10-09 Priority to KR1020047005398A priority patent/KR100933652B1/ko

2002-10-09 Priority to MXPA04003398A priority patent/MXPA04003398A/es

2002-10-09 Priority to DK02801515T priority patent/DK1445258T3/da

2002-10-09 Priority to AT02801515T priority patent/ATE434616T1/de

2002-10-09 Priority to CA2463569A priority patent/CA2463569C/en

2002-10-09 Priority to US10/491,935 priority patent/US7119104B2/en

2002-10-09 Application filed by Nippon Chemiphar Co.,Ltd. filed Critical Nippon Chemiphar Co.,Ltd.

2002-10-09 Priority to EP02801515A priority patent/EP1445258B1/en

2002-10-09 Priority to AU2002335231A priority patent/AU2002335231B2/en

2002-10-09 Priority to JP2003536232A priority patent/JP4276074B2/ja

2002-10-09 Priority to DE60232739T priority patent/DE60232739D1/de

2003-04-24 Publication of WO2003033493A1 publication Critical patent/WO2003033493A1/ja

2004-04-13 Priority to IL161351A priority patent/IL161351A/en

2006-10-06 Priority to US11/544,505 priority patent/US7402597B2/en

Links

239000012190 activator Substances 0.000 title abstract 2
102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 title 1
108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 title 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 4
229910052760 oxygen Inorganic materials 0.000 abstract 4
239000001301 oxygen Substances 0.000 abstract 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
239000011593 sulfur Chemical group 0.000 abstract 3
229910052717 sulfur Inorganic materials 0.000 abstract 3
125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
150000002431 hydrogen Chemical class 0.000 abstract 2
UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
108010015181 PPAR delta Proteins 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000003107 substituted aryl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PCT/JP2002/010472 2001-10-12 2002-10-09 Activateur du recepteur $g(d) active par le proliferateur de peroxisome WO2003033493A1 (fr)

Priority Applications (14)

Application Number	Priority Date	Filing Date	Title
CA2463569A CA2463569C (en)	2001-10-12	2002-10-09	Activator for peroxisome proliferator-activated receptor .delta.
KR1020047005398A KR100933652B1 (ko)	2001-10-12	2002-10-09	페록시좀 증식제 응답성 수용체 δ의 활성화제
MXPA04003398A MXPA04003398A (es)	2001-10-12	2002-10-09	Activador para el receptor o activado con el proliferador de peroxisoma.
DK02801515T DK1445258T3 (da)	2001-10-12	2002-10-09	Aktivator for peroxisomproliferator-aktiveret receptor delta
AT02801515T ATE434616T1 (de)	2001-10-12	2002-10-09	Aktivator des peroxisomproliferator-aktivierten rezeptors delta
US10/491,935 US7119104B2 (en)	2001-10-12	2002-10-09	Activator of peroxisome proliferator-activated receptor delta
EP02801515A EP1445258B1 (en)	2001-10-12	2002-10-09	Activator for peroxisome proliferator-activated receptor delta
BRPI0213243A BRPI0213243B8 (pt)	2001-10-12	2002-10-09	composto heterocíclico aromático contendo um anel oxazol, tiazol ou imidazol, ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
IL16135102A IL161351A0 (en)	2001-10-12	2002-10-09	ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR delta
AU2002335231A AU2002335231B2 (en)	2001-10-12	2002-10-09	Activator for peroxisome proliferator-activated receptor delta
JP2003536232A JP4276074B2 (ja)	2001-10-12	2002-10-09	ペルオキシソーム増殖剤応答性受容体δの活性化剤
DE60232739T DE60232739D1 (de)	2001-10-12	2002-10-09	Aktivator des peroxisomproliferator-aktivierten rezeptors delta
IL161351A IL161351A (en)	2001-10-12	2004-04-13	Activator for PROLIFERATOR-activated prooxisome receptor and medicinal preparations containing it
US11/544,505 US7402597B2 (en)	2001-10-12	2006-10-06	Activator of peroxisome proliferator-activated receptor δ

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001315694		2001-10-12
JP2001-315694		2001-10-12

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
US11/544,505 Continuation US7402597B2 (en)	2001-10-12	2006-10-06	Activator of peroxisome proliferator-activated receptor δ

Publications (1)

Publication Number	Publication Date
WO2003033493A1 true WO2003033493A1 (fr)	2003-04-24

Family

ID=19133818

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/JP2002/010472 WO2003033493A1 (fr)	2001-10-12	2002-10-09	Activateur du recepteur $g(d) active par le proliferateur de peroxisome

Country Status (17)

Country	Link
US (2)	US7119104B2 (ja)
EP (1)	EP1445258B1 (ja)
JP (1)	JP4276074B2 (ja)
KR (1)	KR100933652B1 (ja)
CN (1)	CN1293076C (ja)
AT (1)	ATE434616T1 (ja)
AU (1)	AU2002335231B2 (ja)
BR (1)	BRPI0213243B8 (ja)
CA (1)	CA2463569C (ja)
CY (1)	CY1110355T1 (ja)
DE (1)	DE60232739D1 (ja)
DK (1)	DK1445258T3 (ja)
ES (1)	ES2326411T3 (ja)
IL (2)	IL161351A0 (ja)
MX (1)	MXPA04003398A (ja)
PT (1)	PT1445258E (ja)
WO (1)	WO2003033493A1 (ja)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004093910A1 (ja) *	2003-04-22	2004-11-04	Astellas Pharma Inc.	ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
WO2005060958A1 (en) *	2003-12-19	2005-07-07	Kalypsys, Inc.	(5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
WO2007003581A1 (en)	2005-06-30	2007-01-11	Novo Nordisk A/S	Phenoxy acetic acids as ppar delta activators
WO2007004733A1 (ja) *	2005-07-06	2007-01-11	Nippon Chemiphar Co., Ltd.	ペルオキシソーム増殖剤活性化受容体δの活性化剤
WO2008016175A1 (fr) *	2006-08-03	2008-02-07	Nippon Chemiphar Co., Ltd.	Agent activant de récepteur activé par les proliférateurs des peroxysomes
WO2008143254A1 (ja)	2007-05-21	2008-11-27	Senju Pharmaceutical Co., Ltd.	ＰＰＡＲδアゴニスト含有医薬
JP2009534402A (ja) *	2006-04-18	2009-09-24	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｈｄｌ−ｃの増加、ｌｄｌ−ｃの低下およびコレステロールの低下のために使用されるｐｐａｒ−デルタ作用物質としてのベンゾアゼピン−オキシ−酢酸誘導体
WO2009128558A1 (ja)	2008-04-15	2009-10-22	日本ケミファ株式会社	ペルオキシソーム増殖剤活性化受容体の活性化剤
WO2010047982A1 (en)	2008-10-22	2010-04-29	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2305352A1 (en)	2004-04-02	2011-04-06	Merck Sharp & Dohme Corp.	5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2011043453A1 (ja) *	2009-10-08	2011-04-14	日本ケミファ株式会社	ペルオキシソーム増殖剤活性化受容体の活性化剤
US7943612B2 (en)	2006-03-09	2011-05-17	High Point Pharmaceuticals, Llc	Compounds that modulate PPAR activity, their preparation and use
US7943613B2 (en)	2005-12-22	2011-05-17	High Point Pharmaceuticals, Llc	Compounds, their preparation and use
US7968723B2 (en)	2004-05-05	2011-06-28	High Point Pharmaceuticals, Llc	Compounds, their preparation and use
WO2011106273A1 (en)	2010-02-25	2011-09-01	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8053598B2 (en)	2004-05-05	2011-11-08	High Point Pharmaceuticals, Llc	Compounds, their preparation and use
WO2012027331A1 (en)	2010-08-27	2012-03-01	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2012116145A1 (en)	2011-02-25	2012-08-30	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2014022528A1 (en)	2012-08-02	2014-02-06	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2014119642A1 (ja)	2013-01-31	2014-08-07	千寿製薬株式会社	安定な水性液剤
WO2014119643A1 (ja)	2013-01-31	2014-08-07	千寿製薬株式会社	澄明な水性液剤
WO2014130608A1 (en)	2013-02-22	2014-08-28	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
WO2015051725A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2017195875A1 (ja) *	2016-05-12	2017-11-16	日本ケミファ株式会社	創傷治療剤
WO2018106518A1 (en)	2016-12-06	2018-06-14	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (en)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
US10456406B2 (en)	2013-09-09	2019-10-29	Vtv Therapeutics Llc	Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
WO2022007772A1 (zh)	2020-07-10	2022-01-13	成都凡诺西生物医药科技有限公司	取代苯并咪唑类衍生物及其应用
US11931365B2 (en)	2022-01-25	2024-03-19	Reneo Pharmaceuticals, Inc.	Use of PPAR-delta agonists in the treatment of disease

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1445258E (pt) *	2001-10-12	2009-07-02	Nippon Chemiphar Co	Activador para o receptor delta activado por proliferador de peroxissoma
ES2378435T3 (es)	2003-09-19	2012-04-12	Janssen Pharmaceutica N.V.	�?cidos 4-((fenoxialquil)tio)-fenoxiacéticos y análogos
WO2006029699A1 (en) *	2004-09-11	2006-03-23	Sanofi-Aventis Deutschland Gmbh	7-azaindoles and their use as ppar agonists
US7833513B2 (en) *	2004-12-03	2010-11-16	Rhode Island Hospital	Treatment of Alzheimer's Disease
WO2007030574A2 (en) *	2005-09-07	2007-03-15	Plexxikon, Inc.	1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
JO3006B1 (ar)	2005-09-14	2016-09-05	Janssen Pharmaceutica Nv	املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
BRPI0710266B8 (pt) *	2006-04-18	2021-05-25	Nippon Chemiphar Co	composto, medicamento, e, uso de um composto
WO2008154023A1 (en) *	2007-06-11	2008-12-18	Cerenis Therapeutics S.A.	Novel uses of ppar delta agonists
AU2010282399A1 (en)	2009-08-14	2012-03-01	Cerenis Therapeutics Holding S.A.	Use of PPAR delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases
CA2774999A1 (en)	2009-09-30	2011-04-07	President And Fellows Of Harvard College	Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
US10847272B2 (en) *	2016-12-30	2020-11-24	Nuscale Power, Llc	Control rod drive mechanism (CRDM) with remote disconnect mechanism
US11634387B2 (en)	2019-09-26	2023-04-25	Abionyx Pharma Sa	Compounds useful for treating liver diseases
WO2022189856A1 (en) *	2021-03-08	2022-09-15	Abionyx Pharma Sa	Compounds useful for treating liver diseases
CN115215856B (zh) *	2022-08-19	2024-10-11	沈阳药科大学	一种PPARδ激动剂福那德帕及其中间体的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996020925A1 (en) *	1995-01-06	1996-07-11	Toray Industries, Inc.	Benzene-fused heterocyclic derivative and use of the same
WO2000023442A1 (fr) *	1998-10-16	2000-04-27	Ono Pharmaceutical Co., Ltd.	Derives d'acide carboxylique et medicaments contenant ces derives en tant que principe actif
WO2001079197A1 (en) *	2000-04-14	2001-10-25	Nippon Chemiphar Co.,Ltd.	ACTIVATORS FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ (PPARδ)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5089514A (en)	1990-06-14	1992-02-18	Pfizer Inc.	3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5089541A (en)	1990-11-23	1992-02-18	Shell Oil Company	Removal of hydrogenation catalyst from polymer solutions by contact with activated carbon
GB9027023D0 (en)	1990-12-12	1991-01-30	Wellcome Found	Anti-atherosclerotic aryl compounds
HUT64023A (en)	1991-03-22	1993-11-29	Sandoz Ag	Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
GB9426448D0 (en)	1994-12-30	1995-03-01	Wellcome Found	Process
CA2171702A1 (en)	1995-03-14	1996-09-15	Takashi Sohda	Benzofuran compounds and their use
AU5121796A (en)	1995-05-08	1996-11-29	Nippon Chemiphar Co. Ltd.	2,4-thiazolidinedione or oxazolidinedione derivatives and hy poglycemic agent
HUP9900424A2 (hu)	1996-01-22	1999-05-28	Fujisawa Pharmaceutical Co., Ltd.	Tiazolil-benzfurán-származékok és a vegyületeket tartalmazó gyógyászati készítmények
WO1997028115A1 (en)	1996-02-02	1997-08-07	Merck & Co., Inc.	Antidiabetic agents
US20020032330A1 (en)	1996-12-24	2002-03-14	Yutaka Nomura	Propionic acid derivatives
AU8355998A (en)	1997-07-24	1999-02-16	Yamanouchi Pharmaceutical Co., Ltd.	Medicinal compositions with cholesterol-lowering effect
JP2004506722A (ja) *	2000-08-23	2004-03-04	イーライ・リリー・アンド・カンパニー	ペルオキシソーム増殖因子活性化受容体の調節方法
US7105551B2 (en) *	2000-12-20	2006-09-12	Smithkline Beecham Corporation	Thiazole derivatives for treating PPAR related disorders
GB0031109D0 (en) *	2000-12-20	2001-01-31	Glaxo Group Ltd	Chemical compounds
AU2002233271A1 (en) *	2000-12-20	2002-07-01	Glaxo Group Limited	Substitued oxazoles and thiazoles as hppar alpha agonists
GB0113231D0 (en) *	2001-05-31	2001-07-25	Glaxo Group Ltd	Chemical compounds
AU2002323776B2 (en) *	2001-08-10	2008-07-31	Nippon Chemiphar Co., Ltd.	Activator for peroxisome proliferator-responsive receptor Delta
PT1445258E (pt)	2001-10-12	2009-07-02	Nippon Chemiphar Co	Activador para o receptor delta activado por proliferador de peroxissoma
US6867224B2 (en) *	2002-03-07	2005-03-15	Warner-Lambert Company	Compounds that modulate PPAR activity and methods of preparation

2002
- 2002-10-09 PT PT02801515T patent/PT1445258E/pt unknown
- 2002-10-09 EP EP02801515A patent/EP1445258B1/en not_active Expired - Lifetime
- 2002-10-09 JP JP2003536232A patent/JP4276074B2/ja not_active Expired - Fee Related
- 2002-10-09 DK DK02801515T patent/DK1445258T3/da active
- 2002-10-09 CA CA2463569A patent/CA2463569C/en not_active Expired - Lifetime
- 2002-10-09 ES ES02801515T patent/ES2326411T3/es not_active Expired - Lifetime
- 2002-10-09 WO PCT/JP2002/010472 patent/WO2003033493A1/ja active Application Filing
- 2002-10-09 MX MXPA04003398A patent/MXPA04003398A/es active IP Right Grant
- 2002-10-09 KR KR1020047005398A patent/KR100933652B1/ko not_active Expired - Fee Related
- 2002-10-09 DE DE60232739T patent/DE60232739D1/de not_active Expired - Lifetime
- 2002-10-09 US US10/491,935 patent/US7119104B2/en not_active Expired - Lifetime
- 2002-10-09 IL IL16135102A patent/IL161351A0/xx unknown
- 2002-10-09 BR BRPI0213243A patent/BRPI0213243B8/pt not_active IP Right Cessation
- 2002-10-09 CN CNB028202422A patent/CN1293076C/zh not_active Expired - Fee Related
- 2002-10-09 AU AU2002335231A patent/AU2002335231B2/en not_active Ceased
- 2002-10-09 AT AT02801515T patent/ATE434616T1/de active
2004
- 2004-04-13 IL IL161351A patent/IL161351A/en active IP Right Grant
2006
- 2006-10-06 US US11/544,505 patent/US7402597B2/en not_active Expired - Lifetime
2009
- 2009-08-06 CY CY20091100833T patent/CY1110355T1/el unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996020925A1 (en) *	1995-01-06	1996-07-11	Toray Industries, Inc.	Benzene-fused heterocyclic derivative and use of the same
WO2000023442A1 (fr) *	1998-10-16	2000-04-27	Ono Pharmaceutical Co., Ltd.	Derives d'acide carboxylique et medicaments contenant ces derives en tant que principe actif
WO2001079197A1 (en) *	2000-04-14	2001-10-25	Nippon Chemiphar Co.,Ltd.	ACTIVATORS FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ (PPARδ)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004093910A1 (ja) *	2003-04-22	2004-11-04	Astellas Pharma Inc.	ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
WO2005060958A1 (en) *	2003-12-19	2005-07-07	Kalypsys, Inc.	(5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
EP2305352A1 (en)	2004-04-02	2011-04-06	Merck Sharp & Dohme Corp.	5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US8053598B2 (en)	2004-05-05	2011-11-08	High Point Pharmaceuticals, Llc	Compounds, their preparation and use
US7968723B2 (en)	2004-05-05	2011-06-28	High Point Pharmaceuticals, Llc	Compounds, their preparation and use
EP2298742A1 (en)	2005-06-30	2011-03-23	High Point Pharmaceuticals, LLC	Phenoxy acetic acids as PPAR delta activators
WO2007003581A1 (en)	2005-06-30	2007-01-11	Novo Nordisk A/S	Phenoxy acetic acids as ppar delta activators
US8217086B2 (en)	2005-06-30	2012-07-10	High Point Pharmaceuticals, Llc	Phenoxy acetic acids as PPAR delta activators
US8426473B2 (en)	2005-06-30	2013-04-23	High Point Pharnaceuticals, LLC	Phenoxy acetic acids as PPAR delta activators
US7943669B2 (en)	2005-06-30	2011-05-17	High Point Pharmaceuticals, Llc	Phenoxy acetic acids as PPAR delta activators
JPWO2007004733A1 (ja) *	2005-07-06	2009-01-29	日本ケミファ株式会社	ペルオキシソーム増殖剤活性化受容体δの活性化剤
WO2007004733A1 (ja) *	2005-07-06	2007-01-11	Nippon Chemiphar Co., Ltd.	ペルオキシソーム増殖剤活性化受容体δの活性化剤
US11420929B2 (en)	2005-12-22	2022-08-23	Vtv Therapeutics Llc	Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US10471066B2 (en)	2005-12-22	2019-11-12	Vtv Therapeutics Llc	Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US9663481B2 (en)	2005-12-22	2017-05-30	Vtv Therapeutics Llc	Phenoxy acetic acids and phenyl propionic acids as PPARδ agonists
US9855274B2 (en)	2005-12-22	2018-01-02	Vtv Therapeutics Llc	Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US7943613B2 (en)	2005-12-22	2011-05-17	High Point Pharmaceuticals, Llc	Compounds, their preparation and use
US10947180B2 (en)	2005-12-22	2021-03-16	Vtv Therapeutics Llc	Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US8551993B2 (en)	2005-12-22	2013-10-08	High Point Pharmaceuticals, Llc	Phenoxy acetic acids as PPAR delta activators
US8362016B2 (en)	2005-12-22	2013-01-29	High Point Pharmaceuticals, Llc	Phenyl propionic acids as PPAR delta activators
EP2386540A1 (en)	2005-12-22	2011-11-16	High Point Pharmaceuticals, LLC	Novel compounds, their preparation and use
US7943612B2 (en)	2006-03-09	2011-05-17	High Point Pharmaceuticals, Llc	Compounds that modulate PPAR activity, their preparation and use
JP2009534402A (ja) *	2006-04-18	2009-09-24	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｈｄｌ−ｃの増加、ｌｄｌ−ｃの低下およびコレステロールの低下のために使用されるｐｐａｒ−デルタ作用物質としてのベンゾアゼピン−オキシ−酢酸誘導体
WO2008016175A1 (fr) *	2006-08-03	2008-02-07	Nippon Chemiphar Co., Ltd.	Agent activant de récepteur activé par les proliférateurs des peroxysomes
JP5247686B2 (ja) *	2007-05-21	2013-07-24	千寿製薬株式会社	ＰＰＡＲδアゴニスト含有医薬
US9463185B2 (en)	2007-05-21	2016-10-11	Senju Pharmaceutical Co., Ltd.	Pharmaceutical containing PPAR-delta agonist
RU2449789C2 (ru) *	2007-05-21	2012-05-10	Сэндзю Фармасьютикал Ко., Лтд.	Лекарственное средство, содержащее prarδ агонист
WO2008143254A1 (ja)	2007-05-21	2008-11-27	Senju Pharmaceutical Co., Ltd.	ＰＰＡＲδアゴニスト含有医薬
US8802705B2 (en)	2007-05-21	2014-08-12	Senju Pharmaceutical Co., Ltd.	Pharmaceutical containing PPAR delta agonist
KR101508020B1 (ko) *	2007-05-21	2015-04-06	센주 세이야꾸 가부시키가이샤	Ｐｐａｒδ 아고니스트 함유 의약
WO2009128558A1 (ja)	2008-04-15	2009-10-22	日本ケミファ株式会社	ペルオキシソーム増殖剤活性化受容体の活性化剤
EP3424917A1 (en)	2008-04-15	2019-01-09	Nippon Chemiphar Co., Ltd.	Activator for peroxisome proliferator-activated receptor
WO2010047982A1 (en)	2008-10-22	2010-04-29	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011043453A1 (ja) *	2009-10-08	2011-04-14	日本ケミファ株式会社	ペルオキシソーム増殖剤活性化受容体の活性化剤
WO2011106273A1 (en)	2010-02-25	2011-09-01	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012027331A1 (en)	2010-08-27	2012-03-01	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP3243385A1 (en)	2011-02-25	2017-11-15	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012116145A1 (en)	2011-02-25	2012-08-30	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2014022528A1 (en)	2012-08-02	2014-02-06	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2014119643A1 (ja)	2013-01-31	2014-08-07	千寿製薬株式会社	澄明な水性液剤
US9968679B2 (en)	2013-01-31	2018-05-15	Senju Pharmaceutical Co., Ltd.	Clear aqueous solution
WO2014119642A1 (ja)	2013-01-31	2014-08-07	千寿製薬株式会社	安定な水性液剤
US10709786B2 (en)	2013-01-31	2020-07-14	Senju Pharmaceutical Co., Ltd.	Clear aqueous solution
WO2014130608A1 (en)	2013-02-22	2014-08-28	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
EP3756661A1 (en)	2013-09-09	2020-12-30	vTv Therapeutics LLC	Use of a ppar-delta agonist for treating muscle atrophy
US10456406B2 (en)	2013-09-09	2019-10-29	Vtv Therapeutics Llc	Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
US11096946B2 (en)	2013-09-09	2021-08-24	Vtv Therapeutics Llc	Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
WO2015051725A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
CN109562101A (zh) *	2016-05-12	2019-04-02	日本化学药品株式会社	创伤治疗剂
WO2017195875A1 (ja) *	2016-05-12	2017-11-16	日本ケミファ株式会社	創傷治療剤
WO2018106518A1 (en)	2016-12-06	2018-06-14	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (en)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
WO2022007772A1 (zh)	2020-07-10	2022-01-13	成都凡诺西生物医药科技有限公司	取代苯并咪唑类衍生物及其应用
US11931365B2 (en)	2022-01-25	2024-03-19	Reneo Pharmaceuticals, Inc.	Use of PPAR-delta agonists in the treatment of disease

Also Published As

Publication number	Publication date
BR0213243A (pt)	2005-01-04
ES2326411T3 (es)	2009-10-09
US7119104B2 (en)	2006-10-10
KR100933652B1 (ko)	2009-12-23
IL161351A0 (en)	2004-09-27
CN1293076C (zh)	2007-01-03
US20070027196A1 (en)	2007-02-01
CA2463569C (en)	2012-05-15
CY1110355T1 (el)	2015-04-29
US20050096363A1 (en)	2005-05-05
CN1568323A (zh)	2005-01-19
JPWO2003033493A1 (ja)	2005-02-03
BRPI0213243B1 (pt)	2021-03-16
IL161351A (en)	2012-12-31
AU2002335231B2 (en)	2008-05-08
BRPI0213243B8 (pt)	2021-05-25
CA2463569A1 (en)	2003-04-24
JP4276074B2 (ja)	2009-06-10
MXPA04003398A (es)	2004-11-22
EP1445258A1 (en)	2004-08-11
ATE434616T1 (de)	2009-07-15
PT1445258E (pt)	2009-07-02
EP1445258A4 (en)	2006-01-04
KR20040053164A (ko)	2004-06-23
US7402597B2 (en)	2008-07-22
EP1445258B1 (en)	2009-06-24
DE60232739D1 (de)	2009-08-06
DK1445258T3 (da)	2009-10-12

Legal Events

Date	Code	Title	Description
2003-04-24	AK	Designated states	Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM
2003-04-24	AL	Designated countries for regional patents	Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG
2003-06-25	121	Ep: the epo has been informed by wipo that ep was designated in this application
2003-11-27	DFPE	Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
2004-04-07	WWE	Wipo information: entry into national phase	Ref document number: 2003536232 Country of ref document: JP
2004-04-12	WWE	Wipo information: entry into national phase	Ref document number: 20028202422 Country of ref document: CN Ref document number: 1020047005398 Country of ref document: KR Ref document number: PA/A/2004/003398 Country of ref document: MX
2004-04-13	WWE	Wipo information: entry into national phase	Ref document number: 2463569 Country of ref document: CA Ref document number: 161351 Country of ref document: IL
2004-05-10	WWE	Wipo information: entry into national phase	Ref document number: 2002801515 Country of ref document: EP
2004-05-11	WWE	Wipo information: entry into national phase	Ref document number: 1007/CHENP/2004 Country of ref document: IN
2004-05-12	WWE	Wipo information: entry into national phase	Ref document number: 2002335231 Country of ref document: AU
2004-08-11	WWP	Wipo information: published in national office	Ref document number: 2002801515 Country of ref document: EP
2004-10-29	WWE	Wipo information: entry into national phase	Ref document number: 10491935 Country of ref document: US

Publication	Publication Date	Title
WO2003033493A1 (fr)	2003-04-24	Activateur du recepteur $g(d) active par le proliferateur de peroxisome
WO2003016291A1 (fr)	2003-02-27	Activateur du recepteur $g(d) sensible au proliferateur de peroxysome
AU2001277723A1 (en)	2002-02-25	Ppardelta activators
DE60315265D1 (de)	2007-09-13	Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
MXPA04004037A (es)	2004-07-23	Compuestos novedosos de 1, 2, 4-de triazol.
IL147651A0 (en)	2002-08-14	Isoxazoline derivative and herbicide containing the same as the active ingredient
DK0747374T3 (da)	2002-04-08	Sulfonamidsubstituerede benzopyraner som kaliumkanalaktivatorer
ID30498A (id)	2001-12-13	Senyawa-senyawa turunan amina
AU755654C (en)	2007-03-29	Novel amide compounds and drugs containing the same
WO2003031414A1 (fr)	2003-04-17	Nouveau compose heterocyclique et agent anti-inflammatoire
TWI265161B (en)	2006-11-01	Oxime compounds, their use, and intermediates for their production
EA199901050A2 (ru)	2000-06-26	Новые соединения имидазолина, способ их получения и содержащие их фармацевтические композиции
MX9704435A (es)	1997-10-31	Compuestos de tiazolidinona y agente terapeutico o agente de prevencion para angina de pecho, que comprende los compuestos como un ingrediente activo.
AU6517698A (en)	1998-10-20	Novel anilide compounds and drugs containing the same
MXPA04003086A (es)	2004-09-06	Proceso para sintesis estereoselectiva de 2-hidroximetil-cromanos.
EP1197211A4 (en)	2004-09-01	CANCER PREVENTION AND TREATMENT ACTIVE INGREDIENTS
WO2005095364A8 (ja)	2006-01-05	フェノキシ酢酸誘導体及びそれを用いた医薬
MXPA04005839A (es)	2004-09-10	Nuevos compuestos de benzotiazina y benzotiadiazina un proceso para su preparacion y las composiciones farmaceuticas que los contienen.
TH34907A (th)	1999-09-14	สารประกอบใหม่